Sartorius Stedim Biotech (DIM) Q2 2024 earnings summary

Executive summary

• H1 2024 results met sales and margin targets, but demand recovery remains weak amid persistent market volatility and post-pandemic normalization.

• Bioprocess division sales held steady year-over-year, with strong growth in advanced therapies, while lab division sales declined due to weak end markets, especially in China.

• Profitability remains robust, supported by efficiency programs, though lower volumes and capacity utilization continue to dilute margins.

• Order intake rose 8.5% to €1,558m, reflecting some demand normalization and advanced inventory reductions by customers.

• Workforce reduced to 10,382 as of June 30, 2024, mainly through attrition and expiry of fixed-term contracts.

Financial highlights

• H1 2024 sales revenue: €1,680m (down 2.2% in constant currencies), with Polyplus acquisition contributing about 2 percentage points.

• Q2 sales grew 3.6% after a Q1 decline of 7.6%; recurring business outperformed non-recurring/equipment sales.

• Underlying EBITDA was €471m (margin 28.1%), down 8.8% year-over-year; free cash flow increased to €108m due to reduced CapEx.

• Underlying EPS (ord.): €2.15, down 27.3%; reported net profit: €61m, down 67.6%.

• CapEx as a percentage of sales down to 13.6%.

Outlook and guidance

• Full-year 2024 guidance de-risked: sales expected flat year-over-year, with a range from low single-digit negative to low single-digit positive growth.

• Polyplus expected to contribute 1.5–2 percentage points to group sales.

• Group EBITDA margin guidance set at 27–29% (previously above 30%).

• CapEx ratio expected at ~12%; net debt to EBITDA ratio anticipated around 4 at year-end.

• No change to medium-term targets up to 2028.